there seems to be some heavy resistance around these level with a lot of potential upside.

Hear Hear!

i stand corrected..BB

Galapagos Identifies New Candidate Drug For Arthritis

BRUSSELS (Dow Jones)
Belgian drug discovery company Galapagos NV (GLPG.BT) Monday said it has successfully identified a third candidate drug in its arthritis alliance with GlaxoSmithKline (GSK). The company also reached milestones for other compounds in the alliance, which trigger cash payments totaling EUR5.7 million to Galapagos.

MAIN FACTS:

-This latest preclinical candidate is a small molecule that meets all the chemical and biological criteria set by GSK for a potential new medicine. Galapagos developed the candidate against a novel drug target from its proprietary platform. Galapagos will now start scale-up chemistry and comprehensive safety evaluation, with the aim to initiate Phase I clinical trials early 2011.

We know this paragraph.
The US Food and Drug Administration is reviewing data on possible heart risks with GlaxoSmithKline Plc's diabetes drug Avandia but has not reached any new conclusions, the agency said on Monday.

But I didn't know this (Did I miss it earlier).
The FDA will hold a public meeting in July 2010 to discuss the risks and benefits of the drug, but said in the meantime doctors and patients should continue to use Avandia as directed.

So Avandia is in limbo till at least July.
All the evidence for and against is out there so why the 5 month delay.

Jobs-worthies, justifying their existence!

Sold out today. Not because I have lost confidence in GSK, but feel the market as a whole is in for a double dip due to the financial situation being worse than it looks on the surface. Mainly the PIGS situation and the world finances in general.
So probably won't post again on here for a while, but will continue to watch/read with interest.
Good luck to all still in.

Notifiable Share Interest in JCR Pharmaceuticals Co., Limited

GlaxoSmithKline plc ("GSK") announces that, on 26 March 2010, GSK exercised
stock acquisition rights at an exercise price of JPY650 per share to acquire
1,560,000 Common shares of JCR Pharmaceuticals Co., Limited ("JCR"), a
pharmaceutical company located in Japan and whose shares are traded on the Osaka
Stock Exchange. The details of this transaction have been disclosed in an
announcement issued by JCR to the Osaka Stock Exchange on 26 March 2010.

Following this transaction, GSK's interest, which is held by its wholly owned
subsidiary, Glaxo Group Limited, has increased from 12.05% to 16.73% of the
outstanding Common shares of JCR, making GSK the largest shareholder of JCR.
GSK's total holding represents 16.92% of the total voting rights in JCR. The
details of this transaction have been disclosed in an announcement issued by JCR
to the Osaka Stock Exchange on 26 March 2010.

1st Quarter results.

GlaxoSmithKline 1Q Net Profit +17, Beats Views
By Sten Stovall
Of DOW JONES NEWSWIRES

LONDON (Dow Jones)

GlaxoSmithKline PLC (GSK, GSK.LN) Wednesday beat forecasts with a 17% rise in first-quarter net profit, boosted by sales of its pandemic flu and hepatitis vaccines, its top selling asthma treatment Advair and newer medicines like breast cancer pill Tykerb, as well as further expansion in emerging markets.

Andrew Witty, Glaxo's chief executive officer, said in a statement: "Our sales growth is multi-sourced with good performances in our Pharmaceuticals business, driven by vaccines, respiratory and dermatology products and in our Consumer Healthcare business. In all of these areas, sales were especially dynamic across emerging markets where we continue to gain market share."

GlaxoSmithKline no longer provides a specific numerical outlook.

In the three months to March 31, net profit rose to GBP1.56 billion from GBP1.33 billion in the same period a year earlier. A poll of nine analysts had foreseen net profit rising to GBP1.51 billion.

Sales climbed 8.7% to GBP7.36 billion, beating analyst forecasts of GBP7.28 billion for the latest quarter.

Earnings per share for the first quarter before major restructuring increased 16% from a year earlier, to 30.7 pence.

Glaxo shares rose after the update and, at 1119 GMT, were trading up 1.4% or 17p at 1,231 pence, in a lower London market. The stock has gained around 15% in value over the last 12 months.

GlaxoSmithKline, unlike many of its rivals, has already undergone the bulk of its patent expiries. Under CEO Witty, the company has diversified itself via revamps and acquisitions and is now emerging strongly with a solid pipeline--led by its new autoimmune disease drug Benlysta--and is increasingly focused on growth, particularly in emerging markets and Japan.

Final Results.

Unaudited Preliminary Results Announcement for the year ended 31st December 2010

Strategic progress drives positive underlying sales growth*,
increasing pipeline potential and improved cash generation

Increased dividend and new long-term share buy-back
programme enhance returns to shareholders

EU agency concerned by narcolepsy link to GSK shot

Reuters) - European drugs regulators are continuing a safety review of GlaxoSmithKline's H1N1 flu vaccine Pandemrix and said on Friday they were concerned by further reports of possible links to narcolepsy, a rare sleep disorder.

News from another sector that is arguably undervalued pharmaceutical company Glaxosmithkline report on their third-quarter performances on Wednesday .

Has been out of favour, due to a number of drugs reaching the ends of their patent lives, fears of slowdowns in development pipelines, and increasing competition from developing countries -- although GlaxoSmithKline shares have staged something of a recovery in recent months.

Glaxo shares, at just under 14, on a forward P/E of 12 and offering a 5% yield.

3rd Quarter Results.

GSK delivers strong Q3 performance with underlying sales growth* of 6% and reported sales
growth of 3%

* EPS 28.5p +1% before major restructuring*


* Dividend +6% to 17p; 2011 share buyback expectations
increased to up to GBP2.3 billion

It's taken a long time but GSK seems to be firmly (?) in the saddle
now, I hope!

Initial outcomes of Phase III studies for Relovair

Tuesday February 7

• GlaxoSmithKline will update the market on its annual results. Britain’s biggest drug maker is expected to post revenues of £27.6bn compared with £28.4bn last time and profits of £8.4bn compared with £4.5bn the previous year, when Glaxo’s earnings were hit by a £2.2bn legal charge in the final quarter. Investors will be looking for an update on how Glaxo is allocating funding to its 38 “discovery performance units”, having held a Dragons’ Den-style review to find its most promising research projects.

Final Results.

Unaudited Preliminary Results Announcement for the year ended 31 December 2011

GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders

2011 underlying sales +4% (reported -3%); EPS before major restructuring* 114.1p; total dividends of 75p.

Glaxo invests £500m in UK and builds new factory

Drugmaker GlaxoSmithKline has said it will invest £500m in manufacturing in the UK, including building a new factory in Ulverston, Cumbria.

The investments could create up to 1,000 new jobs, Glaxo said. The biopharmaceutical facility will be its first new UK factory for 40 years.

Glaxo said it was "one of the largest commitments to the UK life-sciences sector in recent years".

1st Quarter Results.

GSK reports sales growth (+2% CER), further R&D delivery, operational leverage and continued
returns to shareholders
- Core* EPS 27.3p (+7%)
* Dividend up 6% to 17p; total 2012 share buyback now
expected to be GBP2-GBP2.5 billion including non-core
OTC disposal proceeds

GSK signs worldwide acquisition for Toctino

Stiefel, a GSK company, today announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea). Toctino is a once-daily oral retinoid and the only prescription medicine specifically approved for the treatment of severe chronic hand eczema unresponsive to potent topical steroids in adults. It is commercially available in 14 countries, approved in an additional 15 countries, and is in a Phase 3 trial in the US. In 2011, worldwide sales of Toctino were £22m.

1st Quarter Results

Summary

■ Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year comparisons:

- Sales +2% excluding divestments (primarily Vesicare and non-core OTC brands)

- Pharmaceuticals and Vaccines sales -2%: US -6% (+4% excl. Vesicare with strong respiratory and oncology performances), Europe -3%, EMAP +8%, Japan -8% (+11% excl. Cervarix)

- Consumer Healthcare +1% (+6% excluding divestments)


■ Continued R&D pipeline progress:

- Positive FDA Advisory Committee recommendation for use of Breo Ellipta in treatment of COPD; FDA Action date 12 May

- MEK monotherapy, MEK/BRAF combination use and albiglutide filed in Europe; dolutegravir granted Priority Review in US; Anoro Ellipta filed in Japan


■ Continued delivery of financial efficiencies, strong cash generation and returns to shareholders:

- Adjusted net cash inflow from operating activities of £1.4 billion (Q1 2012: £1.1 billion)

- Initial phases of new major change programme, including European restructuring, progressing well

- Q1 core tax rate 22.4% reflecting benefit of US R&D tax credit; continue to expect full year core tax rate of around 24%

- Q1 dividend: 18p, +6%; continuing to target share repurchases for the year at £1-2 billion


■ Further measures to drive strategic focus and improve growth profile:

- Strategic review of Lucozade and Ribena completed; decision to pursue divestment subject to appropriate value realisation

- Pharmaceutical tail brands (with 2012 sales of around £3 billion from over 50 brands) to be formed into a Global Established Products portfolio; co-ordinated and reported separately from January 2014


■ 2013 expectations for sales growth (~1%) and core EPS growth (3-4%) unchanged (both at CER)

GSK puts Lucozade and Ribena drink brands up for sale

LONDON | Wed Apr 24, 2013 1:45pm BST
(Reuters) - GlaxoSmithKline is to sell soft drink brands Lucozade and Ribena in a move analysts believe will raise over 1 billion pounds and focus its consumer health business on global products.

The plan was announced on Wednesday alongside first-quarter results that saw sales at Britain's biggest drugmaker drop a slightly smaller-than-expected 3 percent from a year ago.